Therapeutic efficacy of Pudilan Xiaoyan Oral Liquid(PDL)for COVID-19 in vitro and in vivo

作     者：Wei Deng Yanfeng Xu Qi Kong Jing Xue Pin Yu Jiangning Liu Qi Lv Fengdi Li Qiang Wei Linlin Bao Wei Deng;Yanfeng Xu;Qi Kong;Jing Xue;Pin Yu;Jiangning Liu;Qi Lv;Fengdi Li;Qiang Wei;Linlin Bao

作者机构：NHC Key Laboratory of Human Disease Comparative MedicineBeijing Key Laboratory for Animal Models of Emerging and Remerging Infectious DiseasesInstitute of Laboratory Animal ScienceChinese Academy of Medical Sciences and Comparative Medicine CenterPeking Union Medical CollegeBeijingChina 

出 版 物：《Signal Transduction and Targeted Therapy》 (信号转导与靶向治疗（英文）)

年 卷 期：2020年第5卷第1期

页      面：1875-1877页

核心收录：

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：supported by the National Key Research and Development Project of China(Grant No.2016YFD0500304) CAMS initiative for Innovative Medicine of China(Grant No.2016-I2M-2-006) National Mega projects of China for Major Infectious Diseases(Grant Nos.2017ZX10304402,2018ZX10301403) Fundamental Research Funds for CAMS of China(Grant No.2020HY320001) 

主　　题：vivo fir COV 

摘      要：Dear Editor,Coronavirus disease 2019(COVID-19)caused by severe acute respiratory syndrome coronavirus-2(SARS-CoV-2),has rapidly swept through the worldwide,with more than 3 million confirmed *** now,no vaccine or effective therapeutic measures are provided to prevent the SARS-CoV-2 *** medicines have some strong advantages on pharmacokinetics,known side effects,safety and dosing regimens.1 Although remdesivir and chloroquine could effectively inhibit the replication of SARS-CoV-2 in vitro,2 no medicine candidates have been evaluated in vivo by using animal models with SARS-CoV-2 infection.